FTSE MIB
33.568,47 +114,69 (+0,34%) Dow Jones
41.393,78 +297,01 (+0,72%) Nasdaq
17.683,98 +114,30 (+0,65%) Nikkei 225
36.581,76 -251,51 (-0,68%) Petrolio
69,24 +0,27 (+0,39%) Bitcoin EUR
54.061,39 +140,18 (+0,26%)
Nanobiotix S.A. (0QAV.IL)
| Chiusura precedente | 4,7400 |
| Rendimento dall'inizio dell'anno (YTD) | N/D |
| Coefficiente di spesa (netto) | N/D |
| Categoria | N/D |
| Ultimo guadagno in conto di capitale | N/D |
| Valutazione Morningstar | N/D |
| Valutazione di Morningstar (rischio) | N/D |
| Rating di sostenibilità | N/D |
| Attivi netti | N/D |
| Beta (mensile su 5 anni) | N/D |
| Rendimento | N/D |
| Rendimento medio 5a | N/D |
| Turnover portafoglio titoli | N/D |
| Ultimo dividendo | N/D |
| Media per la categoria | N/D |
| Data di inizio disponibilità | N/D |
GlobeNewswireVoting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)PARIS, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: BISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisable2
GlobeNewswireNanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society for Radiation Oncology Waterfall Plot Best Observed Response in Injected Lesions Based on Investigator Assessment Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently
- GlobeNewswire
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
Conference call and live webcast Thursday, October 5th, 2023, at 8:00 AM EDT/2:00pm CESTPARIS and CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the oral presentation of the final readout on primary objectives from Study 102 Dose Expansion—the expansion part of a Phase 1 dos
